Skip to main content
Journal cover image

Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.

Publication ,  Journal Article
Tetef, M; Leong, L; Ahn, C; Akman, S; Chow, W; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Doroshow, JH
Published in: Cancer Invest
1999

Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m2/day over 72 hr, plus cisplatin, 30 mg/m2 for three doses at hours 12, 36, and 60 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3% (1/32 patients; 95% CI, 0-16%) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude that the prolonged infusion of Ara-C in combination with divided doses of cisplatin offers no significant therapeutic advantage.

Published In

Cancer Invest

ISSN

0735-7907

Publication Date

1999

Volume

17

Issue

2

Start / End Page

114 / 117

Location

England

Related Subject Headings

  • Treatment Failure
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Gastrointestinal Diseases
  • Female
  • Drug Administration Schedule
  • Cytarabine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tetef, M., Leong, L., Ahn, C., Akman, S., Chow, W., Margolin, K., … Doroshow, J. H. (1999). Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial. Cancer Invest, 17(2), 114–117.
Tetef, M., L. Leong, C. Ahn, S. Akman, W. Chow, K. Margolin, R. J. Morgan, et al. “Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.Cancer Invest 17, no. 2 (1999): 114–17.
Tetef M, Leong L, Ahn C, Akman S, Chow W, Margolin K, et al. Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial. Cancer Invest. 1999;17(2):114–7.
Tetef, M., et al. “Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.Cancer Invest, vol. 17, no. 2, 1999, pp. 114–17.
Tetef M, Leong L, Ahn C, Akman S, Chow W, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Doroshow JH. Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial. Cancer Invest. 1999;17(2):114–117.
Journal cover image

Published In

Cancer Invest

ISSN

0735-7907

Publication Date

1999

Volume

17

Issue

2

Start / End Page

114 / 117

Location

England

Related Subject Headings

  • Treatment Failure
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Gastrointestinal Diseases
  • Female
  • Drug Administration Schedule
  • Cytarabine